Px HealthCare (Px) makes OWise, the regulated oncology platform that supports people through cancer treatment and that partners build evidence programmes on.
More than 25,000 people with breast and prostate cancer use OWise across the UK, the Netherlands and the United States. What they record about their own treatment becomes structured, longitudinal, post-market approval evidence.
CE-marked Class I Medical Device
Approved for NHS use
More than 25,000 users in the UK, the Netherlands and the US
OWise sits in that gap. Patients record symptoms, side effects and wellbeing as they happen, on a regulated platform, under consent they control. That produces evidence which cannot be reconstructed from claims or hospital records after the fact.
Brand-agnostic education and support content, authored by Px, compliant with ABPI and equivalent codes. Px retains editorial control.
Built with partners around a named therapy or product, on the regulated platform patients already use, in the country-specific version for that market.
Structured, post-market approval real-world evidence, including symptom and tolerability data captured between appointments rather than at scheduled visits.
OWise breast cancer is a CE-marked Class I Medical Device, approved for NHS use, co-designed with breast cancer patients. It supports people through systemic treatment, where tolerability decides whether therapy continues, with a side effect and symptom set specific to breast cancer.
It runs in country-specific versions built on national clinical guidelines in the UK, the Netherlands and the US, and carries the majority of the platform’s longitudinal evidence base.
OWise prostate cancer is a CE-marked Class I Medical Device, approved for NHS use, co-designed with prostate cancer patients. It includes a shared decision making tool for choosing a first treatment, PSA tracking, and monitoring of the symptoms and side effects specific to prostate cancer and men’s health.
Currently available in the UK.
A nationwide study, designed on the platform
With OWise as the core platform, Px designed a UK nationwide real-world observational study, sponsored by a leading pharma company, to capture longitudinal patient-reported outcomes in routine NHS care. The study design was approved by the HRA and the REC, and was presented at the San Antonio Breast Cancer Symposium in 2023.
Fourteen years in oncology
Established by medical scientists in 2012, Px is headquartered in London. OWise has been in use since 2013 and has been independently evaluated in peer-reviewed journals. Founder Dr Anne Bruinvels previously formed and exited a data-mining biotech company listed on the London Stock Exchange. Medical Director Dr David Bruinvels is an occupational physician specialising in oncology and a qualified epidemiologist.
